NZ Herald
  • Home
  • Latest news
  • Herald NOW
  • Video
  • New Zealand
  • Sport
  • World
  • Business
  • Entertainment
  • Podcasts
  • Quizzes
  • Opinion
  • Lifestyle
  • Travel
  • Viva
  • Weather

Subscriptions

  • Herald Premium
  • Viva Premium
  • The Listener
  • BusinessDesk

Sections

  • Latest news
  • New Zealand
    • All New Zealand
    • Crime
    • Politics
    • Education
    • Open Justice
    • Scam Update
  • Herald NOW
  • On The Up
  • World
    • All World
    • Australia
    • Asia
    • UK
    • United States
    • Middle East
    • Europe
    • Pacific
  • Business
    • All Business
    • MarketsSharesCurrencyCommoditiesStock TakesCrypto
    • Markets with Madison
    • Media Insider
    • Business analysis
    • Personal financeKiwiSaverInterest ratesTaxInvestment
    • EconomyInflationGDPOfficial cash rateEmployment
    • Small business
    • Business reportsMood of the BoardroomProject AucklandSustainable business and financeCapital markets reportAgribusiness reportInfrastructure reportDynamic business
    • Deloitte Top 200 Awards
    • CompaniesAged CareAgribusinessAirlinesBanking and financeConstructionEnergyFreight and logisticsHealthcareManufacturingMedia and MarketingRetailTelecommunicationsTourism
  • Opinion
    • All Opinion
    • Analysis
    • Editorials
    • Business analysis
    • Premium opinion
    • Letters to the editor
  • Politics
  • Sport
    • All Sport
    • OlympicsParalympics
    • RugbySuper RugbyNPCAll BlacksBlack FernsRugby sevensSchool rugby
    • CricketBlack CapsWhite Ferns
    • Racing
    • NetballSilver Ferns
    • LeagueWarriorsNRL
    • FootballWellington PhoenixAuckland FCAll WhitesFootball FernsEnglish Premier League
    • GolfNZ Open
    • MotorsportFormula 1
    • Boxing
    • UFC
    • BasketballNBABreakersTall BlacksTall Ferns
    • Tennis
    • Cycling
    • Athletics
    • SailingAmerica's CupSailGP
    • Rowing
  • Lifestyle
    • All Lifestyle
    • Viva - Food, fashion & beauty
    • Society Insider
    • Royals
    • Sex & relationships
    • Food & drinkRecipesRecipe collectionsRestaurant reviewsRestaurant bookings
    • Health & wellbeing
    • Fashion & beauty
    • Pets & animals
    • The Selection - Shop the trendsShop fashionShop beautyShop entertainmentShop giftsShop home & living
    • Milford's Investing Place
  • Entertainment
    • All Entertainment
    • TV
    • MoviesMovie reviews
    • MusicMusic reviews
    • BooksBook reviews
    • Culture
    • ReviewsBook reviewsMovie reviewsMusic reviewsRestaurant reviews
  • Travel
    • All Travel
    • News
    • New ZealandNorthlandAucklandWellingtonCanterburyOtago / QueenstownNelson-TasmanBest NZ beaches
    • International travelAustraliaPacific IslandsEuropeUKUSAAfricaAsia
    • Rail holidays
    • Cruise holidays
    • Ski holidays
    • Luxury travel
    • Adventure travel
  • Kāhu Māori news
  • Environment
    • All Environment
    • Our Green Future
  • Talanoa Pacific news
  • Property
    • All Property
    • Property Insider
    • Interest rates tracker
    • Residential property listings
    • Commercial property listings
  • Health
  • Technology
    • All Technology
    • AI
    • Social media
  • Rural
    • All Rural
    • Dairy farming
    • Sheep & beef farming
    • Horticulture
    • Animal health
    • Rural business
    • Rural life
    • Rural technology
    • Opinion
    • Audio & podcasts
  • Weather forecasts
    • All Weather forecasts
    • Kaitaia
    • Whangārei
    • Dargaville
    • Auckland
    • Thames
    • Tauranga
    • Hamilton
    • Whakatāne
    • Rotorua
    • Tokoroa
    • Te Kuiti
    • Taumaranui
    • Taupō
    • Gisborne
    • New Plymouth
    • Napier
    • Hastings
    • Dannevirke
    • Whanganui
    • Palmerston North
    • Levin
    • Paraparaumu
    • Masterton
    • Wellington
    • Motueka
    • Nelson
    • Blenheim
    • Westport
    • Reefton
    • Kaikōura
    • Greymouth
    • Hokitika
    • Christchurch
    • Ashburton
    • Timaru
    • Wānaka
    • Oamaru
    • Queenstown
    • Dunedin
    • Gore
    • Invercargill
  • Meet the journalists
  • Promotions & competitions
  • OneRoof property listings
  • Driven car news

Puzzles & Quizzes

  • Puzzles
    • All Puzzles
    • Sudoku
    • Code Cracker
    • Crosswords
    • Cryptic crossword
    • Wordsearch
  • Quizzes
    • All Quizzes
    • Morning quiz
    • Afternoon quiz
    • Sports quiz

Regions

  • Northland
    • All Northland
    • Far North
    • Kaitaia
    • Kerikeri
    • Kaikohe
    • Bay of Islands
    • Whangarei
    • Dargaville
    • Kaipara
    • Mangawhai
  • Auckland
  • Waikato
    • All Waikato
    • Hamilton
    • Coromandel & Hauraki
    • Matamata & Piako
    • Cambridge
    • Te Awamutu
    • Tokoroa & South Waikato
    • Taupō & Tūrangi
  • Bay of Plenty
    • All Bay of Plenty
    • Katikati
    • Tauranga
    • Mount Maunganui
    • Pāpāmoa
    • Te Puke
    • Whakatāne
  • Rotorua
  • Hawke's Bay
    • All Hawke's Bay
    • Napier
    • Hastings
    • Havelock North
    • Central Hawke's Bay
    • Wairoa
  • Taranaki
    • All Taranaki
    • Stratford
    • New Plymouth
    • Hāwera
  • Manawatū - Whanganui
    • All Manawatū - Whanganui
    • Whanganui
    • Palmerston North
    • Manawatū
    • Tararua
    • Horowhenua
  • Wellington
    • All Wellington
    • Kapiti
    • Wairarapa
    • Upper Hutt
    • Lower Hutt
  • Nelson & Tasman
    • All Nelson & Tasman
    • Motueka
    • Nelson
    • Tasman
  • Marlborough
  • West Coast
  • Canterbury
    • All Canterbury
    • Kaikōura
    • Christchurch
    • Ashburton
    • Timaru
  • Otago
    • All Otago
    • Oamaru
    • Dunedin
    • Balclutha
    • Alexandra
    • Queenstown
    • Wanaka
  • Southland
    • All Southland
    • Invercargill
    • Gore
    • Stewart Island
  • Gisborne

Media

  • Video
    • All Video
    • NZ news video
    • Herald NOW
    • Business news video
    • Politics news video
    • Sport video
    • World news video
    • Lifestyle video
    • Entertainment video
    • Travel video
    • Markets with Madison
    • Kea Kids news
  • Podcasts
    • All Podcasts
    • The Front Page
    • On the Tiles
    • Ask me Anything
    • The Little Things
  • Cartoons
  • Photo galleries
  • Today's Paper - E-editions
  • Photo sales
  • Classifieds

NZME Network

  • Advertise with NZME
  • OneRoof
  • Driven Car Guide
  • BusinessDesk
  • Newstalk ZB
  • Sunlive
  • ZM
  • The Hits
  • Coast
  • Radio Hauraki
  • The Alternative Commentary Collective
  • Gold
  • Flava
  • iHeart Radio
  • Hokonui
  • Radio Wanaka
  • iHeartCountry New Zealand
  • Restaurant Hub
  • NZME Events

SubscribeSign In
Advertisement
Advertise with NZME.
Home / New Zealand

Hundreds of Kiwis battling leukaemia given hope with funding of new drug

Emma Russell
By Emma Russell
Multimedia Journalist·NZ Herald·
3 Nov, 2019 04:00 PM4 mins to read

Subscribe to listen

Access to Herald Premium articles require a Premium subscription. Subscribe now to listen.
Already a subscriber?  Sign in here

Listening to articles is free for open-access content—explore other articles or learn more about text-to-speech.
‌
Save

    Share this article

Auckland woman Rosemary Blackbourn, pictured with grandson Noah Makea, says the drug venetoclax brought "life-changing" results in fighting her chronic lymphocytic leukaemia. Photo / Supplied

Auckland woman Rosemary Blackbourn, pictured with grandson Noah Makea, says the drug venetoclax brought "life-changing" results in fighting her chronic lymphocytic leukaemia. Photo / Supplied

Hundreds of Kiwis battling leukaemia cancer have been given hope, with Pharmac today announcing funding for a new drug.

For Rosemary Blackbourn, who was diagnosed with chronic lymphocytic leukaemia (CLL) 10 years ago, it's "music to her ears".

The Auckland grandmother has been part of the New Zealand clinical trial for the drug venetoclax during the last six years and has seen "life-changing" results.

"I don't think I'd still be here today if it wasn't for that drug, I am extremely lucky."

READ MORE:
• Pharmac reveals new cancer drugs on the way, contraception more available
• Opposition turns its sights on Pharmac funding
• 'Left on the scrapheap': Pharmac decision bittersweet for MS patients
• Pharmac confirms free access to contraceptives, Mirena and Jaydess

Advertisement
Advertise with NZME.
Advertisement
Advertise with NZME.

At 69, Blackbourn was working as a radiographer for Breast Screening New Zealand when she started getting symptoms and discovered she had CLL.

Her doctor said she had about eight years to live.

"It was a complete shock and the hardest part was I had to wait one year to start chemotherapy as it could potential do more harm than good."

Advertisement
Advertise with NZME.

Blackbourn had six rounds of chemotherapy which she described at "gruelling" and "awful".

"It sucked the life out of me."

Though the chemotherapy worked, her symptoms returned a few years later. It was then she was accepted on to the groundbreaking venetoclax trial.

"For a long time chemo has been the only treatment available to CLL patients so being a part of something new that gave hope was very exciting."

Discover more

New Zealand|crime

Grace Millane murder trial begins today: The key people and what to expect

03 Nov 04:45 PM
New Zealand

Death flowchart: If you were going to die, would you want to know?

06 Nov 09:38 PM
New Zealand

Kiwi medical researchers in surprising finding

01 Nov 04:00 PM
Lifestyle

Could this NZ-made blood test prevent pre-term birth?

03 Nov 04:00 PM

CLL is the most common form of leukaemia in New Zealand, with around 120 people diagnosed annually.

The new drug - sold under the trade names Venclexta and Venclyxto and being funded by Pharmac from December 1 - is an oral tablet and means patients may not have to go through the side effects of chemotherapy and do not have to travel into hospital.

The results from the trial showed 80 per cent of participants improved and 20 per cent went into complete remission.

Pharmac expects around 150 people will benefit from treatment with venetoclax in the first year of funding it, increasing to 230 Kiwis by the end of the second year.

Dr Robert Weinkove, who works as a clinical director at the Malaghan Institute of Medical Research, described the drug as a "big step forward".

"Myself and colleagues across the country use this drug in clinical trials and there are some people who have been purchasing it themselves for various conditions.

Advertisement
Advertise with NZME.

"It's a really promising drug that has proven utility in this leukaemia."

But the treatment came at a big expense: Weinkove put the cost at thousands of dollars each month – or even hundreds of dollars each day.

"I would like to see it become available to a greater number of patients, but this announcement targets that group that is at the greatest clinical need right now."

Weinkove hoped the treatment and similar medicines might ultimately replace the need for chemotherapy altogether in CLL patients.

Pharmac's acting medical director Dr Ken Clark said the agency already funded other medicines for chronic lymphocytic leukaemia, including bendamustine and obinutuzumab.

"Funding venetoclax means patients whose chronic lymphocytic leukaemia has relapsed have another option for treatment."

Advertisement
Advertise with NZME.

Blackbourn's son Ben Hart said he remembers his mum saying she just wanted another 10 years of life to watch her grandchildren grow up.

Now, not only has she lived 10 extra years, which has meant she was able to see her only daughter get married and the birth of more grandchildren, but she's stayed alive to witness others be given the same hope.

About chronic lymphocytic leukaemia (CLL):

• It's the most common type of leukaemia (blood cancer) with 120 Kiwis diagnosed a year.

• CLL is a slow-growing leukaemia that affects a type of white blood cell, which under normal conditions produce antibodies that help protect our bodies against infection and disease.

• Those who do develop signs and symptoms may experience enlarged lymph nodes, fatigue, fever, night sweats, weight loss and frequent infections.

• Although diagnosed on occasion in adults aged 35-55 years, CLL usually affects people over 60 years of age, and is diagnosed more often in men than women.

Advertisement
Advertise with NZME.

• To date, traditional forms of therapy have included chemotherapy, corticosteroid therapy, immunotherapy, radiotherapy and stem cell transplants.

• The new drug is an oral tablet and means patients may not have to go through the side effects of chemotherapy.

Save

    Share this article

Latest from New Zealand

New Zealand

Pedestrian seriously injured on SH8 in Otago

09 Jun 08:59 AM
New Zealand

Customs busts $600k meth haul hidden in portable BBQ

09 Jun 08:28 AM
Crime

'Astonishing' road rage: Campervan driver assaults elderly man on highway

09 Jun 08:00 AM

Why Cambridge is the new home of future-focused design

sponsored
Advertisement
Advertise with NZME.

Latest from New Zealand

Pedestrian seriously injured on SH8 in Otago

Pedestrian seriously injured on SH8 in Otago

09 Jun 08:59 AM

The accident was on State Highway 8, near Roxburgh.

Customs busts $600k meth haul hidden in portable BBQ

Customs busts $600k meth haul hidden in portable BBQ

09 Jun 08:28 AM
'Astonishing' road rage: Campervan driver assaults elderly man on highway

'Astonishing' road rage: Campervan driver assaults elderly man on highway

09 Jun 08:00 AM
Te Pāti Māori attack Greta Thunberg’s ‘abduction’, Israel says she’s safe

Te Pāti Māori attack Greta Thunberg’s ‘abduction’, Israel says she’s safe

09 Jun 07:58 AM
Clean water fuelling Pacific futures
sponsored

Clean water fuelling Pacific futures

NZ Herald
  • About NZ Herald
  • Meet the journalists
  • Newsletters
  • Classifieds
  • Help & support
  • Contact us
  • House rules
  • Privacy Policy
  • Terms of use
  • Competition terms & conditions
  • Our use of AI
Subscriber Services
  • NZ Herald e-editions
  • Daily puzzles & quizzes
  • Manage your digital subscription
  • Manage your print subscription
  • Subscribe to the NZ Herald newspaper
  • Subscribe to Herald Premium
  • Gift a subscription
  • Subscriber FAQs
  • Subscription terms & conditions
  • Promotions and subscriber benefits
NZME Network
  • The New Zealand Herald
  • The Northland Age
  • The Northern Advocate
  • Waikato Herald
  • Bay of Plenty Times
  • Rotorua Daily Post
  • Hawke's Bay Today
  • Whanganui Chronicle
  • Viva
  • NZ Listener
  • What the Actual
  • Newstalk ZB
  • BusinessDesk
  • OneRoof
  • Driven CarGuide
  • iHeart Radio
  • Restaurant Hub
NZME
  • About NZME
  • NZME careers
  • Advertise with NZME
  • Digital self-service advertising
  • Book your classified ad
  • Photo sales
  • NZME Events
  • © Copyright 2025 NZME Publishing Limited
TOP